Page last updated: 2024-11-05

4-xylene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-xylene, also known as para-xylene, is a colorless liquid hydrocarbon with a sweet odor. It is one of the three isomers of xylene. It is mainly obtained from petroleum refining and is used in the production of terephthalic acid, a key component in the production of polyester fibers and resins. 4-xylene is also used as a solvent and as a component of gasoline. The compound is produced on a large scale through the catalytic reforming of naphtha. It is also formed as a byproduct of the production of other chemicals, such as benzene and toluene. 4-xylene has been found to be toxic to aquatic life and may cause respiratory irritation. It is also a potential carcinogen. Despite its potential health risks, 4-xylene is a significant industrial chemical used in the production of many important materials. 4-xylene is studied for its potential applications in various fields, including the synthesis of new materials and the development of new chemical processes. The research on 4-xylene also helps in understanding its environmental impact and the development of methods to reduce its potential harm.'

p-xylene : A xylene with methyl groups at positions 1 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7809
CHEMBL ID31561
CHEBI ID27417
MeSH IDM0098409

Synonyms (85)

Synonym
p-xylenes
C0083
4-xylene
1,4-dimethylbenzol
4-methyltoluene
CHEBI:27417 ,
wln: 1r d1
p-dimethylbenzene
nsc-72419
p-xylol
1,4-xylene
nsc72419
p-xylene, anhydrous, >=99%
inchi=1/c8h10/c1-7-3-5-8(2)6-4-7/h3-6h,1-2h
benzene,1,4-dimethyl
benzene, 1,4-dimethyl-
NCGC00091661-01
xylene, p-
ai3-52255
ccris 910
hsdb 136
chromar
scintillar
einecs 203-396-5
benzene, p-dimethyl-
nsc 72419
xylene, p-isomer
106-42-3
C06756
1,4-dimethylbenzene
p-xylene
p-methyltoluene
PXY ,
para-xylene
68650-36-2
CHEMBL31561 ,
S0649
X0044
X0014
bdbm50008567
AKOS000121124
NCGC00091661-02
paraxylene
BMSE000834
NCGC00258665-01
dtxcid701868
cas-106-42-3
dtxsid2021868 ,
tox21_201113
FT-0689271
68411-39-2
unii-6wac1o477v
ec 203-396-5
p-xylene [un1307] [flammable liquid]
6wac1o477v ,
25951-90-0
187L
STL264212
p-xylene [mi]
4-xylene [hsdb]
1,4-dimethyl benzene
mfcd00008556
J-001588
J-524068
p-xylene, analytical standard
p-xylene, puriss. p.a., >=99.0% (gc)
p-xylene, purum, >=98.0% (gc)
F0001-0120
p-xylene, saj first grade, >=99.0%
p-xylene, for hplc, >=99%
p-xylene, saj special grade, >=99.0%
p-xylene, reagentplus(r), 99%
p-xylene, for synthesis, 99%
p-xylene, pharmaceutical secondary standard; certified reference material
p-xylene 10 microg/ml in methanol
p-xylene 5000 microg/ml in methanol
p-xylene-2,3,5,6-d4
Q3314420
1,4-dimethyl-benzene
136777-61-2
benzene, 1,2(or 1,4)-dimethyl-
EN300-24549
p-xylol (dot)
Z199056432
p-xylene-alpha,alpha'-13c2

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Pretreatment with Aroclor 1254 or beta-naphthoflavone (beta-NF) did not alter the LD50 of 1-NN."( 1-Nitronaphthalene toxicity in rat lung and liver: effects of inhibiting and inducing cytochrome P450 activity.
Carthew, P; Dinsdale, D; Verschoyle, RD; Wolf, CR, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Inhibition of AHH activity was still present 24 h after dosing (41%)."( Lung metabolism of benzo[a]pyrene in rats treated with p-xylene and/or ethanol.
Bogdanffy, MS; Brown, DR; Roberts, AE; Schatz, RA, 1986
)
0.27
"Inhibition of pulmonary CYP4B1 activity by pretreatment of rats with p-xylene decreased the ability of lung microsomes to N-hydroxylate 2-aminofluorene and prevented the lung damage normally seen after dosing with ipomeanol."( CYP4B1 activates 4-ipomeanol in rat lung.
Dinsdale, D; Philpot, RM; Verschoyle, RD; Wolf, CR, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
xylene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
1,4-dimethylbenzene degradation to 4-methylbenzoate39

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.81070.004023.8416100.0000AID485290
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.70020.003041.611522,387.1992AID1159555
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.43740.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588537
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency55.06200.023723.228263.5986AID743223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)2.46990.00000.933210.0000AID32248; AID32280
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EndolysinTequatrovirus T4Kd331.66673.00003.00003.0000AID238119; AID728447; AID728449
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID728450Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID1555240Octanol/water partition co-efficient, log P of compound by UV-spectrophotometry-based shake-flask method
AID728447Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102E double mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID728449Binding affinity to Enterobacteria phage T4 lysozyme L99A mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID728448Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102Q double mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID167125Eye irritation potential accessed using Draize in vivo rabbit eye irritation test2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID32248Inhibition of acetylcholinesterase.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID238119Dissociation constant against T4 lysozyme mutant L99A2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Decoys for docking.
AID32280IC50 against acetylcholinesterase; value ranges from 1-4900 nM.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.
AID1145576Octanol-water partition coefficient, log P of the compound1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Partition coefficients and surface areas of some alkylbenzenes.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Decoys for docking.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (241)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (9.96)18.7374
1990's32 (13.28)18.2507
2000's57 (23.65)29.6817
2010's105 (43.57)24.3611
2020's23 (9.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.07 (24.57)
Research Supply Index5.53 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (1.59%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other247 (98.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]